Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%85 Equity-to-Asset is 0.92 as of Mar. 2026, which is 2% above its 10-year median of 0.90. GuruFocus rates SUSRF with a GF Score™ of 85/100 and a GF Value™ of $19.89. The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 97.07% on this metric.
The historical rank and industry rank for Surgical Science Sweden AB's Equity-to-Asset or its related term are showing as below:
SUSRF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.9 Max: 0.93
Current: 0.92
During the past 11 years, the highest Equity to Asset Ratio of Surgical Science Sweden AB was 0.93. The lowest was 0.32. And the median was 0.90.
SUSRF's Equity-to-Asset is ranked better than 97.07% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs SUSRF: 0.92
Surgical Science Sweden AB (OTCPK:SUSRF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Surgical Science Sweden AB Equity-to-Asset Related Terms
Surgical Science Sweden AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUSRF vs VEEV, BTSG, HQY: Equity-to-Asset Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Equity-to-Asset falls into.
Surgical Science Sweden AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Surgical Science Sweden AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Equity-to-Asset of 0.92 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Surgical Science Sweden AB and its competitors. This is near median its historical median of 0.90. Over the past decade, Surgical Science Sweden AB's Equity-to-Asset has ranged from 0.32 to 0.93. According to the industry distribution chart, Surgical Science Sweden AB ranks #20 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 2.9%.
Is Surgical Science Sweden AB's Equity-to-Asset too high?
Surgical Science Sweden AB's current Equity-to-Asset of 0.92 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.93. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. Surgical Science Sweden AB's value of 0.92 is 91.7% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #20 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Equity-to-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #20 out of 683 companies for Equity-to-Asset. This places Surgical Science Sweden AB in the top 3% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.48. Surgical Science Sweden AB's value of 0.92 is 91.7% above this benchmark. Historically, Surgical Science Sweden AB's own Equity-to-Asset has ranged from 0.32 to 0.93 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.48, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Equity-to-Asset of 0.92 is 91.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Equity-to-Asset is 0.92, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Surgical Science Sweden AB (SUSRF) has a current Equity-to-Asset of 0.92. The stock's GF Value™ is $19.89, compared to a current price of $4.00 — trading 79.9% below its estimated fair value. The current Equity-to-Asset is 0.92, which is near median its 10-year median of 0.90 and 91.7% above the Healthcare Providers & Services industry median of 0.48. Surgical Science Sweden AB's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Equity-to-Asset is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 79.9% below its estimated GF Value™ of $19.89.
Key valuation signals for SUSRF:
Equity-to-Asset: 0.92 (near median its 10-year median of 0.90)
GF Value™: $19.89 vs. price of $4.00 (79.9% below fair value)
Industry Position: 91.7% above the Healthcare Providers & Services median (#20 of 683)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
85GF Score
Get the complete analysis for SUSRF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
